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NKG2D Blockade Prevents
Autoimmune Diabetes in NOD Mice
Autoreactive CD8 T cells are required for both the initial
 cell insult and the final effector phase of diabetes (Katz
et al., 1993; Nagata et al., 1994; Serreze et al., 1994;
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Lauren R. Ehrlich,1 Helene Bour-Jordan,2
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and Lewis L. Lanier1,4,* Wicker et al., 1994). However, the mechanisms by which
the autoreactive CD8T cells mature, expand, and medi-1Department of Microbiology & Immunology and
The Cancer Research Institute ate effector function to accelerate diabetes are un-
known.HSE 1001, Box 0414
2 Diabetes Center Costimulatory molecules on T cells and antigen-pre-
senting cells are critical for the autoimmune response.HSW 1114, Box 0540
University of California, San Francisco There is evidence that CD28, cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4), CD40 ligand, and pro-513 Parnassus Avenue
San Francisco, California 94143 grammed death-1 (PD-1) regulate autoreactive T cell
responses, which influence the development of diabetes3 Julia McFarlane Diabetes Research Centre
Faculty of Medicine in NOD mice (Ansari et al., 2003; Balasa et al., 1997;
Lenschow et al., 1996; Liblau et al., 2002; Salomon andUniversity of Calgary
3330 Hospital Drive NW Bluestone, 2001). NKG2D is a costimulatory receptor
expressed on NK cells, CD8 T cells,  T cells, andCalgary, Alberta T2N 4N1
Canada NKT cells (Cerwenka and Lanier, 2001; Diefenbach et al.,
2002; Wu et al., 1999). NKG2D is expressed on activated/
memory mouse CD8 T cells but is not present on naive
mouse CD8 T cells or CD4 T cells (Diefenbach et al.,Summary
2002). The ligands of NKG2D are known to be “stress-
inducible” molecules, whose expression is triggered byNKG2D is an activating receptor on CD8 T cells and
NK cells that has been implicated in immunity against transformation and infection with viral and bacterial
pathogens (Cerwenka and Lanier, 2001). In mice, thetumors and microbial pathogens. Here we show that
RAE-1 is present in prediabetic pancreas islets of NOD retinoic acid early inducible-1 (RAE-1) family of proteins
have been identified as high-affinity ligands for NKG2Dmice and that autoreactive CD8 T cells infiltrating the
pancreas express NKG2D. Treatment with a nonde- (Cerwenka et al., 2000; Diefenbach et al., 2000). The
expression of the RAE-1 family members is strictly regu-pleting anti-NKG2D monoclonal antibody (mAb) during
the prediabetic stage completely prevented disease by lated in normal cells; therefore, little is expressed on
healthy adult tissues (Cerwenka and Lanier, 2001). Nev-impairing the expansion and function of autoreactive
CD8 T cells. These findings demonstrate that NKG2D ertheless, we found that RAE-1 was expressed on acti-
vated NK cells in NOD mice, but not in C57BL/6 miceis essential for disease progression and suggest a new
therapeutic target for autoimmune type I diabetes. (Ogasawara et al., 2003). These findings suggested dif-
ferential regulation of NKG2D ligands in NOD mice and
prompted us to investigate whether interactions be-Introduction
tween NKG2D and RAE-1 are involved in the develop-
ment of autoimmune diabetes.Type I diabetes (TID) is an autoimmune disease in which
insulin-producing  cells in pancreatic islets are de-
stroyed by autoreactive T cells (Bach, 1994; Castano Results
and Eisenbarth, 1990; Mathis et al., 2001). The nonobese
diabetic (NOD) mouse is widely studied as a model of Expression of RAE-1 in the Pancreas
human TID (Delovitch and Singh, 1997). The develop- of Prediabetic NOD Mice
ment of autoimmune diabetes in NOD mice requires To investigate whether interactions between NKG2D
both CD4 and CD8 T cells (Delovitch and Singh, 1997; and RAE-1 are involved in the development of autoim-
Serreze and Leiter, 2001; Tisch and McDevitt, 1996). mune diabetes, a quantitative RT-PCR assay was devel-
Inflammation of pancreatic islets (insulitis) is observed oped to detect transcripts of all known RAE-1 genes.
in 3-week-old NOD mice, but interestingly, diabetes Abundant RAE-1 transcripts were detected in the pan-
does not develop until 10–20 weeks later, even if T cells creases of late stage prediabetic NOD mice (12–16
have infiltrated into the pancreas (Delovitch and Singh, weeks old) but not in the pancreases of age-matched
1997; DiLorenzo et al., 1998; Liblau et al., 2002). Although BALB/c mice (Figure 1A). Although comparatively less,
recent studies have revealed that autoreactive CD8 RAE-1 transcripts were detected as well in the pancre-
T cells undergo T cell antigen receptor (TcR) avidity ases of 4- to 6-week-old NOD mice. RAE-1 was also
maturation as disease progresses (Amrani et al., 2000), detected in the pancreases of adult NOD.scid mice (that
it is not understood why insulitis does not progress lack B and T cells) (Figure 1B). Together, these results
to diabetes until after 10 weeks of age in NOD mice. suggested that RAE expression is independent of an
ongoing autoimmune response. To examine whether
RAE-1 is selectively upregulated in the pancreas with*Correspondence: lanier@itsa.ucsf.edu
4 These authors contributed equally to this work. age, we compared the levels of RAE-1 transcripts in a
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Figure 1. RAE-1 Is Expressed on CD45-Neg-
ative Islet Cells in Prediabetic NOD Mice
(A) RAE-1 mRNA is expressed in the predia-
betic NOD pancreas, but not the BALB/c pan-
creas. Pancreas from 12- to 16-week-old
NOD and BALB/c mice was harvested, total
RNA was isolated, and RAE-1 transcripts
were measured by quantitative RT-PCR. Data
were normalized to the amount of HPRT
mRNA. Representative data are shown as the
mean of normalized RAE-1 expression SD
(triplicates). Results obtained measuring total
RAE-1 transcripts are shown; similar data
were obtained when RAE-1 transcripts were
quantitated (data not shown).
(B) RAE-1 transcripts are present in predia-
betic NOD pancreas, but not young NOD pan-
creas. RNA was prepared from pancreas of
NOD and NOD.scid mice 4–6 weeks and
12–16 weeks of age and was analyzed as in
(A). Representative data for RAE-1 are
shown.
(C) Pancreas-specific expression of RAE-1 in
prediabetic NOD. RAE-1 transcripts in several
organs from prediabetic NOD (12–16 weeks
of age) and young NOD (4–6 weeks of age)
mice were analyzed by quantitative RT-PCR.
Representative data are shown and ex-
pressed as fold induction of RAE-1 transcrip-
tion. Fold induction was calculated according
to the following formula: Fold induction 
amount of RAE-1 transcript in the prediabetic
NOD organ normalized to HPRT divided by
the amount of RAE-1 transcript in the young
NOD organ normalized to HPRT.
(D) RAE-1 is expressed on CD45 NOD pan-
creas cells. Single-cell suspensions were pre-
pared from the total pancreases isolated from
age-matched female NOD or BALB/c mice.
Total pancreatic cells were stained with anti-
CD45 and anti-RAE-1 mAb and analyzed by
flow cytometry. Cells were gated to evaluate mAb staining of propidium iodide-negative, viable cells. Cells stained with an isotype-matched
control Ig demonstrated the specificity of mAb binding (thin line). CD45 cells were not detected in the pancreas of BALB/c mice.
(E) RAE-1 is expressed on CD45 islets cells in NOD mice. Islets were isolated from prediabetic NOD mice. Single-cell suspensions from islet
cells isolated from the pancreas (upper) and the draining PLN (lower) were stained with anti-CD45 and anti-RAE-1 mAb (CX1) and analyzed
by flow cytometry. Cells were gated to evaluate mAb staining of propidium iodide-negative, viable cells. Cells stained with isotype-matched
control Ig demonstrated the specificity of mAb binding (thin line). All experiments were performed at least twice, and representative data
are shown.
particular organ from young NOD mice compared with the pancreatic lymph nodes (PLN) from these mice. Sin-
gle-cell suspensions from the isolated islets and PLNsame organ in late-stage prediabetic NOD mice. By this
criterion, RAE-1 was increased relatively more in the were stained with anti-RAE-1 and anti-CD45 mAb, and
were analyzed by flow cytometry. RAE-1 was presentpancreas of the prediabetic mice with age, compared
with the liver, spleen, kidney, and thymus (Figure 1C). at low levels on most CD45 islet cells, but not on CD45
hematopoietic cells in the pancreas or PLN (Figures 1DTo determine whether RAE-1 proteins are expressed
on the cell surface, we isolated pancreatic cells from and 1E). These results indicated that RAE-1 transcripts
and proteins were present in the pancreas of prediabeticprediabetic NOD and nondiabetic BALB/c mice. Cells
isolated by enzymatic digestion of the pancreas were NOD mice, but not nondiabetic BALB/c mice, and sug-
gested that expression of RAE-1 may precede diseasestained with anti-RAE-1 and anti-CD45 mAb (which dis-
tinguishes infiltrating CD45 hematopoietic cells from onset and contribute to its progression in NOD mice.
CD45 nonhematopoietic pancreatic islet cells). CD45-
positive hematopoietic lineage cells were detected infil-
trating the prediabetic NOD pancreas, but not the non- CD8 T Cells Infiltrating the NOD
Pancreas Express NKG2Ddiabetic BALB/c pancreas (Figure 1D). RAE-1 proteins
were detected predominantly on the CD45-negative Since the development of diabetes in NOD mice requires
both CD4 and CD8 T cells, we isolated and analyzednonhematopoietic pancreatic cells in NOD mice but
were not found on the pancreatic cells in BALB/c mice. NKG2D expression on T cells in the peripheral immune
tissues and on the infiltrating leukocytes in the pancre-Using density gradient separation techniques, we iso-
lated the islets from NOD pancreases and also harvested ases of NOD mice. As shown in Figure 2A, NKG2D was
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Figure 2. Autoreactive NRP-V7/H-2Kd Tetramer-Positive CD8 T Cells Express NKG2D
(A) CD8 T cells in the NOD pancreas express NKG2D. Leukocytes from spleen, liver, PLN, and pancreas of 10- and 25-week-old NOD mice
were isolated and stained by standard methods. The indicated percentages of NKG2D CD8 T cells (expressed as the percentage of total
CD8 T cells) are shown. Cells stained with isotype-matched control Ig demonstrated the specificity of mAb binding (data not shown).
(B) Pancreatic NKG2D CD8 T cells express high levels of CD44 but not Ly-6C. Leukocytes from the pancreas and PLN from 16-week-old
NOD mice were isolated and stained with anti-CD8, anti-NKG2D, and anti-CD44 or anti-Ly-6C. CD8 T cells were gated and analyzed. Cells
stained with isotype-matched control Ig demonstrated the specificity of mAb binding (data not shown).
(C) NRP-V7/H-2Kd tetramer-positive CD8 T cells express NKG2D and CD44. NRP-V7/H-2Kd tetramer-positive CD8 T cells were detected in
the pancreas and PLN of 16-week-old NOD mice. The indicated percentages of NRP-V7/H-2Kd tetramer-positive CD8 T cells (gated on CD8
T) cells are shown. Cells stained with isotype-matched control Ig or controls for tetramer staining demonstrated the specificity of binding
(data not shown).
(D) NKG2D CD8 T cells accumulated near the islets. Sequential frozen sections of pancreas isolated from prediabetic NOD mice 16 weeks
of age were stained with anti-CD8, anti-CD68 (macrophage marker), anti-NKG2D, and anti-insulin antibodies. Left: phase-contrast differential
image. Center: CD8 (red), NKG2D (green), and insulin (blue). Right: CD68 (red), NKG2D (green), and insulin (blue). Double-positive CD8
NKG2D T cells are yellow. Cells stained with isotype-matched control Ig demonstrated the specificity of binding (data not shown).
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Figure 3. Prevention of Diabetes with Anti-
NKG2D mAb
(A) Treatment with anti-NKG2D mAb from 7
weeks of age prevents diabetes in NOD mice.
NOD mice were treated with anti-NKG2D
mAb (; n 7) (200 	g anti-NKG2D mAb CX5
i.p., twice weekly) or diluent (sterile nonpyro-
genic PBS) (; n  7) from 7 to 25 weeks
of age (indicated by the shaded area in the
figure). Diabetes was diagnosed when the
blood glucose level was greater than 300 mg/
dl on two consecutive measurements. Re-
sults in the control and anti-NKG2D mAb-
treated groups are statistically significant
(p 
 0.001 by using the log rank test).
(B) Blood glucose was measured weekly from
6 to 40 weeks of age in the animals repre-
sented in (A). NOD mice were treated with
anti-NKG2D (n  7) or diluent (sterile PBS)
(n  7) from 7 to 25 weeks of age. Mice were
injected intraperitoneally with 200 	g anti-
NKG2D mAb, twice weekly. Diabetes was di-
agnosed when the blood glucose level was
greater than 300 mg/dl on two consecutive
measurements. Data are shown for blood glu-
cose levels in NOD mice from 6 to 30 weeks
of age.
(C) Treatment with anti-NKG2D mAb at a late
prediabetic stage prevents disease in NOD
mice. NOD mice were treated with anti-
NKG2D mAb (; n  14) or control Ig (; n 
14) from 13 to 25 weeks of age (indicated by
the shaded area in the figure). At 25 weeks
of age, seven anti-NKG2D mAb-treated mice
continued to receive treatment until 30 weeks
of age (). Schedule and dose of antibody
injection and diagnosis of diabetes are as in
(A). Results in the control and anti-NKG2D
mAb-treated groups are statistically signifi-
cant (p 
 0.001 by using the log rank test).
(D) Blood glucose was measured weekly from
12 to 36 weeks of age in the animals repre-
sented in (C). NOD mice were treated with
anti-NKG2D mAb (n  14) or control Ig (n 
14) from 13 to 25 weeks of age. At 25 weeks
of age, seven of the anti-NKG2D mAb-treated
mice continued to receive mAb until 30 weeks of age (). Schedule and dose of antibody injection and diagnosis of diabetes are as described
in (A). Data are shown for blood glucose levels from 12 to 30 weeks of age in NOD mice.
detected on a subset of the CD8 T cells infiltrating peptide from the glucose-6-phosphatase catalytic sub-
unit-related protein (IGRP) that is presented by H-2Kd.the pancreas in 10- and 25-week-old NOD mice. The
percentages of pancreas-infiltrating NKG2D CD8 A mimotope peptide, NRP-V7 (KYNKANVFL), functions
as a superagonist in NOD mice expressing the 8.3 TcRT cells increased with disease progression (Figure 2A).
A smaller fraction of NKG2D CD8 T cells was detected (Amrani et al., 2000; Lieberman et al., 2003; Trudeau et
al., 2003). NRP-V7-reactive CD8 T cells accumulate inin the PLN and spleen (Figures 2A and 2B). Furthermore,
we found that NKG2D CD8 T cells in the pancreas the pancreas of NOD mice and play a critical role in
diabetogenesis (Lieberman et al., 2003; Trudeau et al.,and PLN expressed high levels of CD44, but not Ly-6C
(Figure 2B). A population of CD8 NKG2D leukocytes 2003). We costained CD8 T cells in the pancreas and
PLN with NRP-V7/H-2Kd tetramers and anti-NKG2D. Al-(which did not express CD3; data not shown) was also
observed in the leukocytes infiltrating the NOD pancreas most all NRP-V7/H-2Kd tetramer-positive CD8 T cells
infiltrating the pancreas expressed NKG2D and CD44high(Figure 2A), and many of these cells coexpressed NK
cell and myeloid cell antigens (data not shown). As re- (Figure 2C). Similarly, NKG2D CD8 T cells in the pan-
creas were CD44high, but Ly-6C (Figure 2B), a phenotypeported for normal nondiabetic mouse strains (Jamieson
et al., 2002), we did not detect NKG2D on CD4 T cells consistent with effector CD8 T cells (Cerwenka et al.,
1998). Notably, few NRP-V7/H-2Kd tetramer-positiveor B220 B cells in the pancreas or peripheral lymphoid
tissues of either 10- or 25-week-old NOD mice (data CD8 T cells were detected in the PLN (Figure 2C).
Immunohistochemistry revealed that NKG2D CD8not shown).
Recent studies revealed that a substantial proportion T cells accumulated in the islets of prediabetic NOD
mice, near insulin-producing  cells (Figure 2D).of autoreactive CD8 T cells in NOD mice recognize a
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Treatment with Neutralizing Anti-NKG2D mAb In Vivo that had been treated for 9 weeks with anti-NKG2D (Fig-
Prevents Autoimmune Diabetes ure 4C).
The expression of NKG2D on the infiltrating CD8 T cells The leukocytes isolated from the pancreas and PLN
and NKG2D ligands on the prediabetic islets suggested of NOD mice treated with control Ig or anti-NKG2D mAb
a role in diabetogenesis. This hypothesis was tested by were also analyzed for the presence of antigen-specific
treating prediabetic NOD mice with a neutralizing anti- autoreactive CD8 T cells. Strikingly, infiltration of auto-
NKG2D mAb. The CX5 anti-mouse NKG2D mAb blocks reactive NRP-V7/H-2Kd tetramer-positive CD8 T cells
binding of NKG2D to its ligands, and incubation of into the pancreas was dramatically decreased (75%) in
NKG2D-bearing cells with CX5 resulted in modulation mice treated with anti-NKG2D mAb (Figure 4D). The
and internalization of the receptor (Lodoen et al., 2003; frequency of NRP-V7/H-2Kd tetramer-positive CD8
Ogasawara et al., 2003) (also see Supplemental Figure T cells was also decreased in the PLN, spleen, and
S1 at http://www.immunity.com/cgi/content/full/20/6/ peripheral blood of anti-NKG2D mAb-treated mice,
757/DC1). Importantly, treatment of mice in vivo with compared with control Ig-treated mice (Figures 4D and
CX5 did not deplete NKG2D NK cells or CD8 T cells 4E). NKG2D was not detected on CD8 T cells in mice
(Lodoen et al., 2003 and Supplemental Figure S2). NOD treated with anti-NKG2D mAb (data not shown). Be-
mice were treated with anti-NKG2D mAb from 7–25 cause CX5 is a nondepleting anti-NKG2D mAb (e.g.,
weeks of age. Mice treated with diluent only developed Supplemental Figure S2), the therapy may work by mod-
diabetes beginning at 15 weeks of age and all (n  7) ulation of the receptor (e.g., Supplemental Figure S1)
had disease by 28 weeks (Figures 3A and 3B). In con- and/or inhibition of ligand binding. We also examined
trast, none of the NOD mice treated with anti-NKG2D IFN- production by CD8 T cells isolated from the PLN
(n 7) developed diabetes at 30 weeks of age, although of mice treated in vivo with control Ig or anti-NKG2D
antibody treatment was halted 5 weeks earlier (Figures mAb. Upon stimulation with PMA and ionomycin in vitro,
3A and 3B). IFN- CD8 T cells were detected in cIg-treated NOD
As a more stringent test, we investigated whether anti- mice, whereas fewer IFN-CD8 T cells were observed
NKG2D mAb could prevent onset of disease in 13-week- in mice undergoing anti-NKG2D mAb therapy (Fig-
old prediabetic mice with established insulitis. Mice ure 4F).
given control IgG developed diabetes beginning at 15
weeks of age. By contrast, no diabetes occurred in any NKG2D Blockade Prevents Diabetes in NOD.scid Mice
of the NOD mice during the 12 weeks of anti-NKG2D Receiving Adoptively Transferred T Cells
treatment (Figures 3C and 3D). Remarkably, most of from Diabetic NOD Mice
the anti-NKG2D treated mice remained disease-free 7 To address whether NKG2D blockade affects effector
weeks after halting therapy (Figures 3C and 3D). Thus, CD8 T cells, we adoptively transferred T cells isolated
NKG2D blockade prevented the progression of diabetes from diabetic 16 week-old NOD mice into NOD.scid re-
not only in young mice with insulitis but also in mice at cipients (which lack T cells and do not develop diabetes).
a late prediabetic stage with the imminent onset of islet At the time of transfer, only a small percentage of the
destruction. Side effects of anti-NKG2D mAb treatment
CD8 T cells expressed NKG2D (Figure 5A). However,
were not observed either by gross examination or histo-
5 weeks posttransfer we detected a substantial number
logical analysis (data not shown). Thus, anti-NKG2D
of NKG2D CD8 T cells in the pancreas, PLN, and
mAb treatment is an efficient therapy to prevent diabe-
spleen in the recipient mice (Figure 5A), suggestingtes, at least as long as antibody is administered continu-
expansion of preexisting NKG2D T cells or acquisitionously. These results indicate that NKG2D blockade pre-
of NKG2D on the transferred CD8 T cells. Approxi-vents the progression of diabetes not only in young mice
mately 15% of the CD8 T cells infiltrating the pancreaswith insulitis but also in a later prediabetic stage.
in cIg-treated recipient mice were NRP-V7/H-2Kd tetra-To determine the mechanism of anti-NKG2D mAb-
mer-positive, whereas significantly fewer were foundmediated therapy, we analyzed the leukocytes isolated
in anti-NKG2D mAb-treated mice (Figures 5B and 5C).from the pancreas and PLN of control Ig and anti-NKG2D
NKG2D was present on most NRP-V7/H-2Kd tetramer-mAb-treated NOD mice. CD8 T cells coexpressing
positive autoreactive CD8 T cells in the control Ig-NKG2D and high levels of CD44 were present in the
treated NOD mice but was not detected on the micepancreas of control Ig-treated mice. As expected,
receiving anti-NKG2D mAb therapy (Figure 5C). Al-NKG2D expression was significantly reduced on CD8
though diabetes developed in all control Ig-treatedT cells, but CD44 expression was identical in the pan-
NOD.scid mice receiving T cells from diabetic NOD mice,creas of mice treated with anti-NKG2D mAb compared
none of the anti-NKG2D mAb-treated mice developedto that of mice treated with control Ig (Figure 4A). By
diabetes while undergoing therapy (Figure 5D).contrast, CD8T cells expressing NKG2D were relatively
To determine whether anti-NKG2D treatment blockedinfrequent in the PLN of both control and anti-NKG2D
expansion of pathogenic CD8 T cells in the NOD.scidmAb-treated mice, suggesting preferential localization
recipient mice, we stopped anti-NKG2D mAb treatmentof the NKG2D CD8 T cells in the pancreas (consistent
after 8 weeks, when all control Ig-treated mice had suc-with the results presented in Figure 2 for untreated NOD
cumbed to disease. Four weeks after halting anti-mice). Immunohistochemical analysis of frozen sections
NKG2D therapy, diabetes developed in the majority ofof pancreas from control Ig-treated mice indicated
NOD.scid mice that had received T cells from diabeticabundant CD8 T cells expressing NKG2D in the pan-
NOD donors (Figure 5D). Furthermore, at this time therecreas of 16-week-old NOD mice treated with control Ig
was evidence for expansion of NRP-V7/H-2Kd tetramer-(Figure 4B). In contrast, many fewer CD8 T cells were
present in the healthy pancreas of 16-week-old mice positive NKG2D CD8 T cells in the NOD.scid mice
Immunity
762
Figure 4. Infiltration of NKG2DCD8 T Cells into the Islets and Prevention by Anti-NKG2D mAb Treatment
(A) Leukocytes infiltrating the pancreas and pancreatic lymph node cells of 11-week-old NOD mice treated with control Ig (cIg) or anti-NKG2D
mAb (beginning at 7 weeks of age) were stained with anti-CD8, anti-NKG2D, and anti-CD44. Cells were analyzed by flow cytometry, and
coexpression of NKG2D and CD44 gated on CD8 T cells is shown. Cells stained with isotype-matched control Ig demonstrated the specificity
of mAb binding (data not shown). Cells obtained from the mice treated with anti-NKG2D mAb in vivo did not stain with a polyclonal PE-
conjugated goat anti-rat IgG antibody, indicating that the cells were not coated with the CX5 anti-NKG2D mAb (data not shown).
(B) Infiltration of NKG2D CD8 T cells into the islets of 16-week-old NOD mice treated with control Ig from 7 weeks of age. Frozen pancreas
sections were prepared and stained from 16-week-old NOD mice treated with control Ig. Left: DAPI (nuclei) staining. Right: CD8 (red), NKG2D
(green), and insulin (blue). Cells stained with isotype-matched control Ig demonstrated the specificity of binding (data not shown).
(C) Infiltration of CD8 T cells into the islets was inhibited by anti-NKG2D mAb treatment. Pancreas sections from a 16-week-old NOD mice
treated with anti-NKG2D from 7 weeks of age were prepared and stained. Left: DAPI (nuclei) staining. Right: CD8 (red), NKG2D (green), and
insulin (blue). Cells stained with isotype-matched control Ig demonstrated the specificity of binding (data not shown).
(D) Accumulation of autoreactive NRP-V7/H-2Kd tetramer-positive CD8 T cells in the pancreas was suppressed by anti-NKG2D mAb treatment.
Leukocytes were isolated from pancreases and PLN of 18-week-old NOD mice treated with anti-NKG2D mAb or control Ig from 13 weeks of
age. The indicated percentages of NRP-V7/H-2Kd tetramer-positive CD8 T cells (gated on CD8 T cells) are shown. Cells stained with isotype-
matched control Ig or controls for tetramer staining demonstrated the specificity of binding (data not shown).
(E) Lymphocytes from spleen and peripheral blood were stained with NRP-V7/H-2Kd tetramer and anti-CD8 mAb. The indicated percentages
were NRP-V7/H-2Kd tetramer-positive cells (gated on the CD8 T cell population). Cells stained with isotype-matched control Ig or controls
for tetramer staining demonstrated the specificity of binding (data not shown).
(F) Pancreatic lymph node cells were isolated from 25-week-old NOD mice treated with control Ig (cIg) or anti-NKG2D beginning at 13 weeks
of age, as indicated, and cultured with PMA (20 ng/ml) and ionomycin (500 ng/ml) and brefeldin A (5 	g/ml) for 6 hr. Intracellular IFN- was
detected by immunofluorescent staining and flow cytometry. Cells stained with isotype-matched control Ig demonstrated specificity of binding
(data not shown).
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Figure 5. Adoptive Transfer Experiment of
NOD T Cells into NOD.scid Recipients
(A) NKG2D CD8 T cells were detected in
the pancreas, PLN, and spleen of NOD.scid
mice transplanted with NOD T cells. Prior to
adoptive transfer, purified T cells from a dia-
betic NOD donor were stained with anti-CD8
and anti-NKG2D (top left). Five weeks after
transfer, cells harvested from the pancreas,
PLN, and spleen were stained with anti-CD8
and anti-NKG2D (upper panels) or anti-
NKG2D and anti-CD44 (lower panels). The
percentages of NKG2D CD8T cells (gated
on CD8T cells) are shown.
(B and C) Accumulation of autoreactive NRP-
V7/H-2Kd tetramer-positive CD8 T cells was
suppressed by anti-NKG2D treatment in
NOD.scid mice receiving adoptively trans-
ferred T cells from diabetic NOD mice.
NOD.scid mice transplanted with T cells from
diabetic NOD mice were treated with anti-
NKG2D mAb or control Ig, beginning at the
time of transfer, and mice were analyzed 10
weeks after transfer. The indicated percent-
ages of autoreactive NRP-V7/H-2Kd tetramer-
positive CD8 T cells were detected (gated
on live cells [B] or CD8T cells [C]). Represen-
tative data are shown. In (A)–(C), cells stained
with isotype-matched control Ig or controls
for tetramer staining demonstrated the speci-
ficity of binding (data not shown).
(D) Diabetes was prevented by anti-NKG2D
treatment in NOD.scid mice transplanted with
T cells from diabetic NOD mice. Five-week-
old NOD.scid mice that received adoptively
transferred T cells from diabetic NOD mice
were treated with anti-NKG2D mAb (; n 
6) or control Ig (; n  7) from 5 to 14 weeks
of age. Mice were injected intraperitoneally
with 200 	g anti-NKG2D mAb CX5, twice
weekly. Diabetes was diagnosed when the
blood glucose level was greater than 300
mg/dl on two consecutive measurements.
(E) Expansion of autoreactive NRP-V7/H-2Kd
tetramer-positive CD8 T cells after stopping
treatment with anti-NKG2D mAb or control Ig. Four weeks after anti-NKG2D mAb or control Ig treatment was ceased in NOD.scid mice
transplanted with T cells from diabetic NOD mice, animals were sacrificed, and the pancreases were analyzed for infiltrating NRP-V7/H-2Kd
tetramer-positive, NKG2D CD8 T cells. Cells stained with isotype-matched control Ig or controls for tetramer staining demonstrated the
specificity of binding (data not shown). Representative data are shown.
(Figure 5E). These results indicated that anti-NKG2D TcR-transgenic NOD mice were 90% NRP-V7/H2Kd
tetramer positive (Verdaguer et al., 1997), but did notmAb treatment inhibited the expansion and/or accumu-
lation of NKG2D CD8 T cells in the pancreas. The express NKG2D (Figure 6A). Two days later, the trans-
ferred CFSE-labeled 8.3 TcR-transgenic NOD CD8rapid progression to diabetes shortly after halting ther-
apy suggested that the effector T cells might have been T cells infiltrating the pancreas of mice treated with
control Ig expressed NKG2D (Figure 6B) and were al-controlled, rather than depleted, during the period of
antibody treatment. ready proliferating; however, no dilution of CFSE was
observed in the transferred T cells present in the pancre-
atic or mesenteric lymph nodes (Figure 6C). At days 4Anti-NKG2D mAb Therapy Prevents Expansion
of Autoreactive CD8 T Cells in the Pancreas and 8 posttransfer, the CFSE-labeled 8.3 TcR-trans-
genic T cells in the pancreas and pancreatic lymphOur finding of fewer NRP-V7/H-2Kd tetramer-positive
CD8 T cells in the pancreas of anti-NKG2D-treated nodes, but not the mesenteric lymph nodes, of mice
treated with control Ig showed extensive proliferationmice was consistent with the possibility that mAb ther-
apy blocked expansion of the autoreactive T cells. To (Figure 6C). In striking contrast, NKG2D was not de-
tected on the cell surface of the transferred CFSE-directly test this hypothesis, 8.3 TcR-transgenic T cells
were labeled with CFSE, adoptively transferred into 10- labeled 8.3 TcR-transgenic CD8 T cells in the pancreas
of NOD mice treated with anti-NKG2D mAb (Figure 6B).week-old NOD recipients and treated with either control
Ig or anti-NKG2D mAb (Figure 6). Before transfer, donor Staining with a PE-conjugated goat anti-rat IgG antibody
failed to detect any positive cells in the mice treatedCD8 T cells from the lymph nodes and spleens of 8.3
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Figure 6. Autoreactive 8.3 TcR-Transgenic CD8 T Cell Proliferation in the Pancreas Was Inhibited by Anti-NKG2D mAb Treatment
(A) NKG2D was not expressed on 8.3 TcR-transgenic NOD T cells before adoptive transfer. Lymphocytes were isolated from the lymph nodes
and spleen of young 8.3 TcR-transgenic NOD mice, and 8.3 TcR-transgenic NOD T cells were purified by magnetic cell sorting. Prior to T cell
transfer, 8.3 TcR-transgenic NOD T cells were stained with anti-CD8 and NRP-V7/H-2Kd tetramers or anti-NKG2D and analyzed by flow
cytometry, as shown. Cells stained with isotype-matched control Ig or controls for tetramer staining demonstrated the specificity of binding
(data not shown).
(B) NKG2D was expressed on 8.3 TcR-transgenic NOD T cells in the pancreas. Two days after adoptive transfer of 8.3 TcR-transgenic NOD
T cells, leukocytes were isolated from the pancreas of mice that were treated with control Ig or anti-NKG2D mAb CX5 at the time of cell
transfer. Cells were stained with NRP-V7/H-2Kd tetramers and anti-NKG2D, and were analyzed by flow cytometry. Expression of NKG2D on
the adoptively transferred T cells (identified by gating on NRP-V7/H-2Kd tetramer-positive cells) is shown.
(C and D) Anti-NKG2D mAb CX5 inhibits the proliferation of 8.3 TcR-transgenic CD8 NOD T cells in the pancreas. CFSE-labeled 8.3 TcR-
transgenic NOD T cells (1  107) were transferred into 10-week-old wild-type NOD mice (day 0). Recipient NOD mice were treated with cIg
or anti-NKG2D mAb CX5 (200 	g) on days 1, 1, and 5. After transfer, recipient NOD mice were sacrificed, and leukocytes were isolated and
analyzed from the pancreas, pancreatic lymph node (PLN), and mesenteric lymph node (MLN). Cells shown in (C) were gated on viable CD8-
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in vivo with anti-NKG2D mAb, indicating that the cells to cells expressing its RAE-1 ligands. Therefore, treat-
were not simply coated with the rat anti-NKG2D mAb ment with anti-NKG2D mAb may block interactions be-
(data not shown). Furthermore, the expansion of these tween autoreactive NKG2DCD8 T cells and RAE-1-
8.3 TcR-transgenic CD8 T cells in the pancreas was bearing cells in the pancreas, thereby preventing T cell
substantially inhibited compared with the mice treated expansion. A second mechanism may involve the ability
with control Ig (Figure 6C). Interestingly, treatment with of CX5 mAb to rapidly modulate and internalize the re-
anti-NKG2D mAb had a much more profound effect on ceptor (Supplemental Figure S1 at http://www.immunity.
the proliferation of CFSE-labeled 8.3 TcR-transgenic com/cgi/content/full/20/6/757/DC1). Again, this may
T cells infiltrating the pancreas compared with cells in serve to remove NKG2D from the cell surface of T cells,
the lymph nodes. Expansion of the endogenous CFSE- preventing binding to RAE-1-bearing pancreatic tissues.
unlabeled) T cells in the pancreas detected with the Because CX5 mAb modulates NKG2D, we cannot ex-
NRP-V7/H2Kd tetramer was also diminished by treat- clude the possibility that the receptor-bearing cells
ment with anti-NKG2D mAb, compared with control Ig become desensitized to ligand as a consequence of
treated mice. Quantitation of the proliferation of the adop- mAb-induced signaling. In either case, the data directly
tively transferred 8.3 TcR-transgenic T cells infiltrating the implicate the NKG2D receptor in the functional develop-
pancreas in control Ig and anti-NKG2D mAb-treated NOD ment of effector functions of the pathogenic CD8T cells
mice indicated a profound effect of anti-NKG2D therapy and suggest the anti-NKG2D mAb functions therapeuti-
on expansion of the autoreactive antigen-specific CD8 cally to block receptor-mediated signals in the absence
T cells (Figure 6D and Supplemental Figure S3). of frank cell depletion. Furthermore, our findings demon-
strate that anti-NKG2D mAb effectively prevents diabe-
Discussion tes, even when administrated relatively late during dis-
ease progression. This is in striking contrast with most
In this study, we demonstrate that NKG2D is involved treatments reported in the NOD mouse, which are only
in the development of autoimmune diabetes. We found effective when administered at a much younger age.
that islet cells in the prediabetic NOD mice express Why RAE-1 genes are expressed preferentially in the
NKG2D ligands and autoreactive CD8 T cells infiltrating pancreas of NOD mice is unresolved. One possibility is
the pancreas express NKG2D. Because NKG2D is not that pancreatic cells inadvertently express RAE-1 genes
present on naive mouse CD8 T cells but is induced as a consequence of the NOD genetic background and
only after TcR-mediated activation (Diefenbach et al., this is one factor predisposing these mice to diabetes.
2002), NKG2D blockade probably does not prevent the Our finding of RAE-1 transcripts in the pancreas of NOD-
initial antigen priming. Interestingly, the frequency of .scid mice indicates that autoreactive T cells are not
NKG2D CD8 T cells in the PLN was lower than in required to induce these genes; however, we cannot
the pancreas, suggesting that these autoreactive CD8 exclude that the onset of insulitis might cause increased
T cells acquired NKG2D either as they exit the PLN or
expression of NKG2D ligands. The susceptibility of hu-
in the pancreas, or that NKG2D CD8 T cells expand
mans and NOD mice to type I diabetes has been mapped
preferentially in the pancreas. Anti-NKG2D mAb-treated
to several insulin-dependent diabetic loci (Idd) (Wicker
NOD mice had fewer autoreactive NRP-V7/H-2Kd tetra-
et al., 1995). While none of these Idd is located on mousemer-positive CD8T cells in the pancreas and peripheral
chromosome 10, in proximity to RAE-1, certain Iddlymphoid tissues and produced less IFN- upon ex vivo
genes might indirectly influence the induction or expres-stimulation. Moreover, adoptive transfer experiments
sion of these NKG2D ligands.with CFSE-labeled 8.3 TcR-transgenic CD8 T cells
Groh and colleagues (Groh et al., 2003) reported thatdemonstrated that anti-NKG2D mAb treatment prefer-
NKG2D was detected on CD4 T cells isolated from theentially inhibited expansion of these autoreactive T cells
synovial fluids of patients with rheumatoid arthritis, andin the pancreas. These results are most compatible with
MICA, a ligand for human NKG2D, was present on syn-an effect of anti-NKG2D on autoreactive CD8 T cells.
oviocytes in the affected joints. Additionally, NKG2DHowever, NKG2D also is expressed on NK cells, and
was induced on human T cells by proinflammatory cyto-NKG2D blockade also might serve to suppress the ef-
kines, including IL-15 (Roberts et al., 2001) and TNF-fector functions of these cells, which may contribute to
(Groh et al., 2003). Therefore, while NKG2D may providethe NKG2D-dependent pathogenesis.
beneficial in surveillance against cancer and infections,Although we excluded cell depletion as a potential
there is emerging evidence that this system may havemechanism of disease prevention, anti-NKG2D mAb
a detrimental role in some autoimmune disorders. Ourtherapy may have several effects on the activation of
findings that NKG2D blockade is an efficient therapy forautoreactive CD8 T cells. First, the CX5 anti-NKG2D
type I diabetes suggests a new strategy for the manage-mAb was originally selected for its ability to block the
binding of a soluble recombinant NKG2D fusion protein ment of human autoimmune diseases.
positive lymphocytes. Results shown as histograms with the percentages of proliferating CFSE-labeled T cells are presented in Supplemental
Figure S3. (D) The percentages of CFSE-labeled cells in the control Ig (open bars) and anti-NKG2D mAb (closed bars) -treated mice that had
undergone one or more divisions (i.e., proliferating cells) on days 2, 3, and 4 posttransfer are depicted, calculated by the following formula:
% proliferating cells  (Total CFSE NRP-V7/H-2Kd tetramer CD8 cells  nondividing CFSE NRP-V7/H-2Kd tetramer CD8 cells)  100/
Total CFSE NRP-V7/H-2Kd tetramer CD8 cells. These results were reproducible (two independent experiments), and representative data
are shown.
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Experimental Procedures sawara et al., 2003). The universal primers used to detect all known
RAE-1 transcripts were: sense, 5-CTAGTGCCACCTGGGAATTCA-
3; anti-sense 5-CATCATTAGCTGATCTCCAGCTCA-3, and theMice
NOD mice were purchased from Taconic (Germantown, NY). NOD. probe was 5-6-FAM-CATCAGTGACAGTTACTTCTTCACCTTCTA
CACAGAGA-Tamra-3. Total RNA was treated with DNase I, andscid mice were purchased from the Jackson Laboratory (Bar Harbor,
ME). 8.3 TcR-transgenic NOD mice have been described (Verdaguer then first-strand cDNA was synthesized by using random hexamer
primers. The cycling conditions for real-time PCR were: 50C for 10et al., 1997). All mice were maintained under specific pathogen-
free conditions in the UCSF animal facility, and experiments were min, followed by 50 cycles at 95C for 30 s, and 60C for 2 min.
Data were analyzed by using the Sequence Detector v1.7 Analysisperformed according to the guidelines of the UCSF Committee on
Animal Research. Diabetes was diagnosed when the blood glucose Software (Applied Biosystems). Statistical analysis was performed
by using a two-sample t test.level was greater than 300 mg/dl on two consecutive measurements.
The blood glucose levels were measured by using a blood glucose
monitor (Walgreens, Deerfield, IL). NOD T Cells Transferred into NOD.scid Mice
T cells were isolated from spleens and lymph nodes of diabetic 16-
week-old NOD mice by magnetic cell sorting using a MACS (MiltenyiReagents, Cytokines, and Antibodies
Biotec Inc., Germany). T cells (purity98%) were enriched by nega-Anti-mouse NKG2D mAb, clones CX5 and CX6 (rat IgG1 isotype),
tive selection with depletion of CD19, CD24, and MHC class IIwere generated as described (Ogasawara et al., 2003), and anti-
cells. 7.5  106 T cells were transferred into 4- to 5-week-oldmouse NKG2D mAb clone 191004 (rat IgG2a isotype) was generated
NOD.scid mice by injection into the tail vain. Blood glucose levelsin a collaborative project with Dr. J.P. Houchins (R&D Systems,
in adoptively transferred mice were examined weekly.Minneapolis, MN). All anti-NKG2D mAbs recognize the NKG2D ex-
tracellular domain and efficiently block the binding of NKG2D to its
Adoptive Transfer of 8.3 TcR-Transgenic T Cells into NOD Miceligands. For in vivo injection, we used purified CX5 antibody that
Adoptive T cell transfer was performed as previously describeddid not contain detectable endotoxin (
0.3 pg/injection). Control
(Serra et al., 2002). In brief, 8.3 TcR-transgenic lymphocytes wererat IgG was purchased from Sigma (St. Louis, MO). Anti-mouse pan
isolated from the lymph nodes and spleens. T cells (purity 95%)RAE-1 mAb (clone 186107, rat IgG2b isotype) was generated in a
were enriched by negative selection by magnetic sorting using acollaborative project with Dr. J.P. Houchins and binds to RAE-1,
MACS. 1  107 T cells labeled with CFSE (5 	M) were transferred, , , and NRP-V7/H-2Kd and TUM/H-2Kd (control) tetramers were
into 10-week-old NOD mice by injection in the tail vain on day 0.produced as described (Amrani et al., 2000) or from the NIH Tetramer
Anti-NKG2D mAb (CX5) or cIg (200 	g/injection) was injected intoFacility (Atlanta, GA). TUM/ H-2Kd tetramer did not bind to NRP-V7/
the recipient NOD mice on days 1, 1, and 5.H-2Kd tetramer-positive cells (data not shown). Other antibodies
were purchased from BD Pharmingen or eBiosocience (San
AcknowledgmentsDiego, CA).
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Immunofluorescence, Flow Cytometry, and Microscopy
Received: November 24, 2003For detection of NKG2D, cells (1  106) were stained with 0.25 	g
Revised: April 15, 2004biotinylated or PE-labeled anti-NKG2D mAb (clone 191004). Cells
Accepted: April 21, 2004were costained with FITC-conjugated anti-CD8, APC-conjugated
Published: June 15, 2004anti-CD8, FITC-conjugated anti-CD44, or FITC-conjugated anti-Ly-
6C. To detect RAE-1, cells were stained with a biotinylated anti-pan
ReferencesRAE-1 mAb that recognizes all five known RAE-1 proteins (i.e., RAE-
1, , , , and ) (Lodoen et al., 2003) or anti-RAE-1 mAb (clone
Amrani, A., Verdaguer, J., Serra, P., Tafuro, S., Tan, R., and Santama-CX1) (Ogasawara et al., 2003). PE-conjugated streptavidin or APC-
ria, P. (2000). Progression of autoimmune diabetes driven by avidityconjugated streptavidin was used to detect biotinylated mAbs. The
maturation of a T-cell population. Nature 406, 739–742.cells were incubated with mAbs for 20 min and washed with PBS
Ansari, M.J., Salama, A.D., Chitnis, T., Smith, R.N., Yagita, H., Akiba,containing 0.01% NaN3. Cells were analyzed by using a FACSCalibur
H., Yamazaki, T., Azuma, M., Iwai, H., Khoury, S.J., et al. (2003).(Becton Dickinson, San Jose, CA) or a small desktop Guava Personal
The programmed death-1 (PD-1) pathway regulates autoimmuneCytometer with Guava ViaCount and Guava Express software (Hay-
diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198, 63–69.ward, CA). Viable lymphocyte populations were gated based on
forward and side scatter profiles and by lack of propidium iodide Bach, J.F. (1994). Insulin-dependent diabetes mellitus as an autoim-
staining. For immunohistochemistry, organs were snap frozen in mune disease. Endocr. Rev. 15, 516–542.
OCT media, and sections were prepared and stained by conven- Balasa, B., Krahl, T., Patstone, G., Lee, J., Tisch, R., McDevitt, H.O.,
tional techniques. The images were acquired using a Deltavision and Sarvetnick, N. (1997). CD40 ligand-CD40 interactions are neces-
microscope (Applied Precision, Issaquah, WH), and the computa- sary for the initiation of insulitis and diabetes in nonobese diabetic
tional deconvolution was carried out by using softWoRx software mice. J. Immunol. 159, 4620–4627.
(Applied Precision).
Castano, L., and Eisenbarth, G.S. (1990). Type-I diabetes: a chronic
autoimmune disease of human, mouse, and rat. Annu. Rev. Immunol.
Quantitative RT-PCR
8, 647–679.
Quantitative (real-time) PCR was carried out by using an ABI 7700
Cerwenka, A., and Lanier, L.L. (2001). Ligands for natural killer cell(Applied Biosystems) instrument, according to the manufacturer’s
receptors: redundancy or specificity. Immunol. Rev. 181, 158–169.instructions. Probes were purchased from Applied Biosystems.
RAE-1 specific probes and primers were described previously (Oga- Cerwenka, A., Carter, L.L., Reome, J.B., Swain, S.L., and Dutton,
NKG2D Blockade Prevents Type I Diabetes
767
R.W. (1998). In vivo persistence of CD8 polarized T cell subsets Salomon, B., and Bluestone, J.A. (2001). Complexities of CD28/B7:
CTLA-4 costimulatory pathways in autoimmunity and transplanta-producing type 1 or type 2 cytokines. J. Immunol. 161, 97–105.
tion. Annu. Rev. Immunol. 19, 225–252.Cerwenka, A., Bakker, A.B., McClanahan, T., Wagner, J., Wu, J.,
Serra, P., Amrani, A., Han, B., Yamanouchi, J., Thiessen, S.J., andPhillips, J.H., and Lanier, L.L. (2000). Retinoic acid early inducible
Santamaria, P. (2002). RAG-dependent peripheral T cell receptorgenes define a ligand family for the activating NKG2D receptor in
diversification in CD8 T lymphocytes. Proc. Natl. Acad. Sci. USAmice. Immunity 12, 721–727.
99, 15566–15571.Delovitch, T.L., and Singh, B. (1997). The nonobese diabetic mouse
Serreze, D.V., and Leiter, E.H. (2001). Genes and cellular require-as a model of autoimmune diabetes: immune dysregulation gets
ments for autoimmune diabetes susceptibility in nonobese diabeticthe NOD. Immunity 7, 727–738.
mice. Curr. Dir. Autoimmun. 4, 31–67.Diefenbach, A., Jamieson, A.M., Liu, S.D., Shastri, N., and Raulet,
Serreze, D.V., Leiter, E.H., Christianson, G.J., Greiner, D., andD.H. (2000). Ligands for the murine NKG2D receptor: expression
Roopenian, D.C. (1994). Major histocompatibility complex classby tumor cells and activation of NK cells and macrophages. Nat.
I-deficient NOD-B2mnull mice are diabetes and insulitis resistant.Immunol. 1, 119–126.
Diabetes 43, 505–509.Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A.M., Hsia,
Tisch, R., and McDevitt, H. (1996). Insulin-dependent diabetes melli-J.K., Vivier, E., and Raulet, D.H. (2002). Selective associations with
tus. Cell 85, 291–297.signaling proteins determine stimulatory versus costimulatory activ-
ity of NKG2D. Nat. Immunol. 3, 1142–1149. Trudeau, J.D., Kelly-Smith, C., Verchere, C.B., Elliott, J.F., Dutz, J.P.,
Finegood, D.T., Santamaria, P., and Tan, R. (2003). Prediction ofDiLorenzo, T.P., Graser, R.T., Ono, T., Christianson, G.J., Chapman,
spontaneous autoimmune diabetes in NOD mice by quantification ofH.D., Roopenian, D.C., Nathenson, S.G., and Serreze, D.V. (1998).
autoreactive T cells in peripheral blood. J. Clin. Invest. 111, 217–223.Major histocompatibility complex class I-restricted T cells are re-
quired for all but the end stages of diabetes development in non- Verdaguer, J., Schmidt, D., Amrani, A., Anderson, B., Averill, N.,
and Santamaria, P. (1997). Spontaneous autoimmune diabetes inobese diabetic mice and use a prevalent T cell receptor alpha chain
gene rearrangement. Proc. Natl. Acad. Sci. USA 95, 12538–12543. monoclonal T cell nonobese diabetic mice. J. Exp. Med. 186, 1663–
1676.Groh, V., Bruhl, A., El-Gabalawy, H., Nelson, J.L., and Spies, T.
Wicker, L.S., Leiter, E.H., Todd, J.A., Renjilian, R.J., Peterson, E.,(2003). Stimulation of T cell autoreactivity by anomalous expression
Fischer, P.A., Podolin, P.L., Zijlstra, M., Jaenisch, R., and Peterson,of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl.
L.B. (1994). Beta 2-microglobulin-deficient NOD mice do not developAcad. Sci. USA 100, 9452–9457.
insulitis or diabetes. Diabetes 43, 500–504.Guo, Z., Mital, D., Shen, J., Chong, A.S., Tian, Y., Foster, P., Sankary,
Wicker, L.S., Todd, J.A., and Peterson, L.B. (1995). Genetic controlH., McChesney, L., Jensik, S.C., and Williams, J.W. (1998). Immuno-
of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol.suppression preventing concordant xenogeneic islet graft rejection
13, 179–200.is not sufficient to prevent recurrence of autoimmune diabetes in
nonobese diabetic mice. Transplantation 65, 1310–1314. Wu, J., Song, Y., Bakker, A.B., Bauer, S., Spies, T., Lanier, L.L., and
Phillips, J.H. (1999). An activating immunoreceptor complex formedJamieson, A.M., Diefenbach, A., McMahon, C.W., Xiong, N., Carlyle,
by NKG2D and DAP10. Science 285, 730–732.J.R., and Raulet, D.H. (2002). The role of the NKG2D immunoreceptor
in immune cell activation and natural killing. Immunity 17, 19–29.
Katz, J., Benoist, C., and Mathis, D. (1993). Major histocompatibility
complex class I molecules are required for the development of insul-
itis in non-obese diabetic mice. Eur. J. Immunol. 23, 3358–3360.
Lenschow, D.J., Herold, K.C., Rhee, L., Patel, B., Koons, A., Qin,
H.Y., Fuchs, E., Singh, B., Thompson, C.B., and Bluestone, J.A.
(1996). CD28/B7 regulation of Th1 and Th2 subsets in the develop-
ment of autoimmune diabetes. Immunity 5, 285–293.
Liblau, R.S., Wong, F.S., Mars, L.T., and Santamaria, P. (2002). Auto-
reactive CD8 T cells in organ-specific autoimmunity: emerging tar-
gets for therapeutic intervention. Immunity 17, 1–6.
Lieberman, S.M., Evans, A.M., Han, B., Takaki, T., Vinnitskaya, Y.,
Caldwell, J.A., Serreze, D.V., Shabanowitz, J., Hunt, D.F., Nathenson,
S.G., et al. (2003). Identification of the beta cell antigen targeted by
a prevalent population of pathogenic CD8 T cells in autoimmune
diabetes. Proc. Natl. Acad. Sci. USA 100, 8384–8388.
Lodoen, M., Ogasawara, K., Hamerman, J.A., Arase, H., Houchins,
J.P., Mocarski, E.S., and Lanier, L.L. (2003). NKG2D-mediated natu-
ral killer cell protection against cytomegalovirus is impaired by viral
gp40 modulation of retinoic acid early inducible 1 gene molecules.
J. Exp. Med. 197, 1245–1253.
Mathis, D., Vence, L., and Benoist, C. (2001). beta-Cell death during
progression to diabetes. Nature 414, 792–798.
Nagata, M., Santamaria, P., Kawamura, T., Utsugi, T., and Yoon,
J.W. (1994). Evidence for the role of CD8 cytotoxic T cells in the
destruction of pancreatic beta-cells in nonobese diabetic mice. J.
Immunol. 152, 2042–2050.
Ogasawara, K., Hamerman, J.A., Hsin, H., Chikuma, S., Bour-Jordan,
H., Chen, T., Pertel, T., Carnaud, C., Bluestone, J.A., and Lanier,
L.L. (2003). Impairment of NK cell function by NKG2D modulation
in NOD mice. Immunity 18, 41–51.
Roberts, A.I., Lee, L., Schwarz, E., Groh, V., Spies, T., Ebert, E.C.,
and Jabri, B. (2001). NKG2D receptors induced by IL-15 costimulate
CD28-negative effector CTL in the tissue microenvironment. J. Im-
munol. 167, 5527–5530.
